Clinical Trial Results:
A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with type 2 diabetes with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
Summary
|
|
EudraCT number |
2009-016258-41 |
Trial protocol |
DE SK SI FR |
Global completion date |
03 Feb 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 May 2016
|
First version publication date |
09 Apr 2015
|
Other versions |
|
Summary report(s) |
1245.23 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.